Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): What are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?

Expert Opinion on Drug Safety

Volumn 14, Issue 9, 2015, Pages 1445-1455

  Husain, Nazik Elmalaika ^a   Hassan, Abdallah Tarig ^b   Elmadhoun, Wadie M ^c   Ahmed, Mohamed H ^d  

^a UNIVERSITY OF KHARTOUM   (Sudan)

^b Department of Pharmacy ^*  (Sudan)

^c NILE VALLEY UNIVERSITY   (Sudan)

^d MILTON KEYNES UNIVERSITY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Atorvastatin; Coronary heart disease; Ezetimibe; Fatty liver; Hyperlipidemia; Insulin resistance; Liptruzet

Indexed keywords

ATORVASTATIN; CREATINE KINASE; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ATORVASTATIN PLUS EZETIMIBE; AZETIDINE DERIVATIVE; DRUG COMBINATION; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ANGIONEUROTIC EDEMA; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DIET RESTRICTION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE ABSORPTION; KIDNEY FAILURE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; MONOTHERAPY; MUSCLE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PANCREATITIS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); RHABDOMYOLYSIS; SIDE EFFECT; THROMBOCYTOPENIA; VESICULAR RASH; ANIMAL; BLOOD; DRUG APPROVAL; DRUG COMBINATION; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIA TYPE II;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; DRUG APPROVAL; DRUG COMBINATIONS; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIA TYPE II; INSULIN RESISTANCE; PYRROLES;

EID: 84939816756     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1063613     Document Type: Article

References (71)

1. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007; 192(2): 432-7
2. Goldenberg MM. Pharmaceutical approval update. P T 2013; 38(11): 705-7
3. Her AY, Kim JY, Kang SM, et al. Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. J Cardiovasc Pharmacol Ther 2010; 15(2): 167-74
4. Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004; 24(8): 1454-9
5. Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 2004; 279(48): 50630-8
6. Konrad RJ, Troutt JS, Cao G. Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis 2011; 10: 38
7. Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev 2015; 3: CD008226
8. Ahmed MH, Khalil AA. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant. Saudi J Kidney Dis Transpl 2010; 21(6): 1021-9
9. Nutescu EA, Shapiro NL. Ezetimibe: A selective cholesterol absorption inhibitor. Pharmacotherapy 2003; 23(11): 1463-74
10. Constance C, Ben-Yehuda O, Wenger NK, et al. Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: Attainment of European and Canadian guideline lipid targets in high-risk subjects >/=65 years. Lipids Health Dis 2014; 13: 13
11. Conard SE, Bays HE, Leiter LA, et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008; 102(11): 1489-94
12. Leiter LA, Bays H, Conard S, et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008; 102(11): 1495-501
13. Conard S, Bays H, Leiter LA, et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab 2010; 12(3): 210-18
14. Teramoto T, Sawada T, Iwamoto K, Daida H. Clinical efficacy and tolerability of Ezetimibe in combination with Atorvastatin in Japanese patients with Hypercholesterolemia-Ezetimibe Phase IV randomized controlled trial in patients with Hypercholesterolemia. Curr Ther Res Clin Exp 2012; 73(1-2): 16-40
15. Vargo R, Adewale A, Behm MO, et al. Prediction of clinical irrelevance of PK differences in atorvastatin using PK/PD models derived from literature-based meta-analyses. Clin Pharmacol Ther 2014; 96(1): 101-9
16. Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin 2007; 23(4): 767-75
17. Lee SH, Park S, Kang SM, et al. Effect of atorvastatin monotherapy and lowdose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia. J Cardiovasc Pharmacol Ther 2012; 17(1): 65-71
18. Weffald LA, Flach LA. Myopathy associated with atorvastatin-ezetimibe combination therapy. Pharmacotherapy 2007; 27(2): 309-11
19. Bays HE, Chen E, Tomassini JE, et al. Fixed-dose combination ezetimibe +atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model. Fundam Clin Pharmacol 2015; 29(2): 209-18
20. Yang YC, Chang WT, Huang SK, Liau I. Characterization of the pharmaceutical effect of drugs on atherosclerotic lesions in vivo using integrated fluorescence imaging and Raman spectral measurements. Anal Chem 2014; 86(8): 3863-8
21. Prasad A, Pratim Datta P, Roy R, et al. Comparative study of ezetimibe and atorvastatin alone and in combination on lipid profile in rats. Mater Sociomed 2013; 25(3): 192-5
22. Yasim A, Ozbag D, Kilinc M, et al. Effect of atorvastatin and ezetimibe treatment on serum lipid profile and oxidative state in rats fed with a highcholesterol diet. Am J Med Sci 2010; 339(5): 448-52
23. Matsue Y, Matsumura A, Suzuki M, et al. Differences in action of atorvastatin and ezetimibe in lowering low-density lipoprotein cholesterol and effect on endothelial function: randomized controlled trial. Circ J 2013; 77(7): 1791-8
24. Luo P, Li L, Wang LX, et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genet Mol Res 2014; 13(2): 2377-84
25. Lins LC, Franca CN, Fonseca FA, et al. Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients. Cell Biochem Biophys 2014; 70(1): 687-96
26. Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004; 148(3): 447-55
27. Foody JM, Toth PP, Tomassini JE, et al. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Vasc Health Risk Manag 2013; 9: 719-27
28. Uemura Y, Watarai M, Ishii H, et al. Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol 2012; 59(1): 50-6
29. Azar M, Valentin E, Badaoui G, et al. Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent. Am J Cardiol 2011; 107(11): 1571-4
30. Padhy BM, Yadav R, Gupta YK. Hypolipidaemic and anti-inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia. Singapore Med J 2013; 54(2): 90-5
31. Azar RR, Badaoui G, Sarkis A, et al. Effect of ezetimibe/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent. Am J Cardiol 2010; 106(2): 193-7
32. Holvoet P, Jenny NS, Schreiner PJ, Multi-Ethnic Study of Atherosclerosis. The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007; 194(1): 245-52
33. Makela KM, Traylor M, Oksala N, et al. Association of the novel single-nucleotide polymorphism which increases oxidized low-density lipoprotein levels with cerebrovascular disease events. Atherosclerosis 2014; 234(1): 214-17
34. Li L, Zhang M, Su F, et al. Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes. Lipids Health Dis 2015; 14(1): 10
35. Packard C. Did we IMPROVE-IT: thoughts on LDL targeting post-trial? Expert Rev Cardiovasc Ther 2015; 12: 1-2
36. Laires PA, Ejzykowicz F, Hsu TY, et al. Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal. J Med Econ 2015; 1-8
37. Deushi M, Nomura M, Kawakami A, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007; 581(29): 5664-70
38. Ichimori S, Shimoda S, Goto R, et al. Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes. J Diabetes Investig 2012; 3(2): 179-84
39. Tamaki N, Ueno H, Morinaga Y, Shiiya T. Nakazato M. Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 2012; 19(6): 532-8
40. Ahmed MH, Ali A. Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first? Scand J Gastroenterol 2014; 49(5): 521-7
41. Ahmed MH, Hamad MA, Routh C, Connolly V. Statins as potential treatment for cholesterol gallstones: An attempt to understand the underlying mechanism of actions. Expert Opin Pharmacother 2011; 12(17): 2673-81
42. Ioannou GN, Van Rooyen DM, Savard C, et al. Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crownlike structures during resolution of NASH. J Lipid Res 2015; 56(2): 277-85
43. Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus lowdose atorvastatin compared with higherdose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol 2007; 49(10): 1035-42
44. Ben-Yehuda O, Wenger NK, Constance C, et al. The comparative efficacy of ezetimibe added to atorvastatin 10 mg versus uptitration to atorvastatin 40 mg in subgroups of patients aged 65 to 74 years or greater than or equal to 75 years. J Geriatr Cardiol 2011; 8(1): 1-11
45. Zieve F, Wenger NK, Ben-Yehuda O, et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Am J Cardiol 2010; 105(5): 656-63
46. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 2003; 107(19): 2409-15
47. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010; 35(2): 139-51
48. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 2011; 377(9784): 2181-92
49. Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004; 126(3): 749-55
50. Abraldes JG, Albillos A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: A randomized controlled trial. Gastroenterology 2009; 136(5): 1651-8
51. Eshraghian A, Kamyab AA. Rhabdomyolysis developing secondary to atorvastatin therapy in a patient with liver cirrhosis. Intern Med 2013; 52(7): 823-5
52. Chang CH, Kusama M, Ono S, et al. Assessment of statin-associated muscle toxicity in Japan: A cohort study conducted using claims database and laboratory information. BMJ open 2013; 3(4): e002040
53. Mackay JW, Fenech ME, Myint KS. Acute rhabdomyolysis caused by combination therapy with atorvastatin and warfarin. Br J Hosp Med (Lond) 2012; 73(2): 106-7
54. Wilinski J, Dabrowski M. Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3, 227 patients. Przegl Lek 2013; 70(6): 373-6
55. Vrablik M, Zlatohlavek L, Stulc T, et al. Statin-associated myopathy: from genetic predisposition to clinical management. Physiol Res 2014; 63(Suppl 3): S327-34
56. Boonmuang P, Nathisuwan S, Chaiyakunapruk N, et al. Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database. Drug Saf 2013. [Epub ahead of print]
57. Franco D, Henao Y, Monsalve M, et al. [Hypolipidemic agents drug interactions: Approach to establish and assess its clinical significance. Structured review]. Farm Hosp 2013; 37(6): 539-57
58. Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet 2013; 52(10): 815-31
59. Patel AM, Shariff S, Bailey DG, et al. Statin toxicity from macrolide antibiotic coprescription: A population-based cohort study. Ann Intern Med 2013; 158(12): 869-76
60. Cziraky MJ, Willey VJ, McKenney JM, et al. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol 2013; 7(2): 102-8
61. Gigante A, Giraldi GD, Gasperini ML, et al. Rhabdomyolysis after midazolam administration in a cirrhotic patient treated with atorvastatin. World J Gastrointest Pharmacol Ther 2014; 5(3): 196-9
62. Ara R, Pandor A, Tumur I, et al. Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: A Markov model. Am J Cardiovasc Drugs 2008; 8(6): 419-27
63. Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2, 722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009; 265(5): 568-80
64. Gandhi N, Lenton R, BhartiaM, et al. Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome. SpringerPlus 2014; 3: 14
65. Weffald LA, Flach LA. Myopathy associated with atorvastatin-ezetimibe combination therapy. 2007. Available from: http: //www. ncbi. nlm. nih. gov/pubmed/17253923
66. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010; 375(9716): 735-42
67. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: A meta-analysis. Jama 2011; 305(24): 2556-64
68. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012; 172(2): 144-52
69. Athyros VG, Mikhailidis DP. Pharmacotherapy: statins and new-onset diabetes mellitus- A matter for debate. Nat Rev Endocrinol 2012; 8(3): 133-4
70. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Lipid-lowering agents and new onset diabetes mellitus. Expert Opin Pharmacother 2010; 11(12): 1965-70
71. Liptruzet: A combination of ezetimibe and atorvastatin. Med Lett Drugs Ther 2013; 55(1419): 49-50